Canaccord Genuity Maintains a 'Hold' on Vertex (VRTX); Q4/10: Likely Telaprevir Launch and Advancing Pipeline Make 2011 a Pivotal Yr
Tweet Send to a Friend
Canaccord Genuity maintains a 'Hold' on Vertex (NASDAQ: VRTX), raises PT from $35 to $37.
Canaccord analyst, Adam Cutler, says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst, Adam Cutler, says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
